Steve Warren, a giant in the field of human genetics, died in June at age 67. In the realm of autism research, he may be best known for having co-discovered the gene FMR1, mutations in which cause fragile X syndrome, a leading inherited cause of intellectual disability and autism. Before the human...
Latest News
Cambridge, Mass. – Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the close of a $60 million financing led by The Column Group. The financing includes participation from existing investors Atlas Venture, Foresite Capital,...
AMHERST, Mass. – Tuberculosis, caused by the bacterium Mycobacterium tuberculosis (Mtb) kills upwards of 1.6 million people a year, making it one of the leading causes of death by an infectious agent worldwide—and that number is only growing larger. How, exactly, Mtb evades the immune system isn’t yet known, but...
Irvine, Calif. — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, announced that the company will present a preclinical poster at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting, being held in Salt...
PHILADELPHIA – Renovacor, Inc. (NYSE: RCOR), an early-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science. “We are excited to...
CHAPEL HILL, N.C. — Renovion Inc., a biopharmaceutical company focused on restoring lung health in patients with bronchiectasis and other lung diseases, announced that adult patient enrollment is complete in the Phase 2 CLIMB study of ARINA-1 in non-CF bronchiectasis patients. CLIMB is a US based, randomized, double-blind, placebo-controlled Phase...
San Diego, California, London, UK, and Houston, Texas – Replay, a genome writing company reprogramming biology by writing and delivering big DNA, and The University of Texas MD Anderson Cancer Center, today announced that the Food & Drug Administration (FDA) has issued a ‘safe to proceed’ for the Investigational New...
San Diego, California, London, UK, and Houston, Texas, March 11, 2024 – Replay, a genome writing company reprogramming biology by writing, designing, and delivering big DNA, today announced that the first patient has been dosed in the Phase 1/2 study of NY-ESO-1 TCR/IL-15 NK, an engineered T-Cell Receptor Natural Killer...
Beijing, China – Medullary thyroid carcinoma (MTC) has been the focus of research in the field of thyroid cancer management in the last 20 years along with recurrent laryngeal nerve, according to a new study that analyzed trends in the post-operative management of thyroid cancer between 2003 and 2022. “Future...
MIAMI, FLORIDA – Few standard treatments have been available for advanced myelofibrosis, a bone marrow disorder characterized by excessive scar tissue that disrupts the normal production of blood cells But new research conducted by investigators at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and...